早发性卵巢功能不全患者生育力改善策略的研究进展

doi:10.12280/gjszjk.20210001

摘要/Abstract

摘要：

早发性卵巢功能不全（premature ovarian insufficiency,POI）是指女性40岁以前出现卵巢功能衰退,其主要特征为闭经或月经稀发、低雌激素症状和生育力下降。POI与绝经不同,其并非卵巢功能的完全衰退,POI患者在较长时间内仍可出现间歇性卵巢功能恢复。部分POI患者仍有生育需求,但POI不孕患者的生育治疗手段有限,治疗效果不理想,治疗方案仍在不断探索。通过相关的病例报道及文献复习,总结部分常见的POI患者促生育治疗的方法,主要对药物、手术、卵母细胞体外激活、干细胞移植及注射富含血小板血浆等治疗方法的治疗原理、临床疗效、临床应用的可行性及存在的局限性进行分析。

关键词: 早发性卵巢功能不全, 原发性卵巢功能不全, 生育力, 卵巢, 妊娠

Abstract:

Premature ovarian insufficiency (POI) is defined as the decline of ovarian function in women before the age of 40. The main characteristics are amenorrhea or oligomenorrhea, symptoms of low estrogen, and decreased fertility. POI is different from menopause. It is not due to the complete decline of ovarian function. Patients with POI can still experience intermittent ovarian function recovery for a long time. Some POI patients have fertility needs, but the fertility treatments for those patients are limited, and the treatment effect is not ideal. It is need to optimize and personalize the fertility treatment for those POI patients with the fertility needs. This review summarizes some common fertility treatments for POI patients through relevant case reports and references, including drug treatment, surgery, in vitro activation of oocytes, stem cell transplantation, and injection of platelet-rich plasma. Meanwhile, the therapeutic principles, clinical efficacy, feasibility and limitations of clinical application were also reviewed.

Key words: Premature ovarian insufficiency, Primary ovarian insufficiency, Fertility, Ovary, Pregnancy

杜洁冰, 杨一华. 早发性卵巢功能不全患者生育力改善策略的研究进展[J]. 国际生殖健康/计划生育, 2021, 40(5): 397-401.

DU Jie-bing, YANG Yi-hua. Fertility Improvement Strategies for Patients with Premature Ovarian Insufficiency[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(5): 397-401.

参考文献 35

[1]	Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency[J]. Hum Reprod, 2016, 31(5):926-937. doi: 10.1093/humrep/dew027. doi: 10.1093/humrep/dew027 URL
[2]	Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure[J]. J Clin Endocrinol Metab, 2011, 96(12):3864-3872. doi: 10.1210/jc.2011-1038. doi: 10.1210/jc.2011-1038 pmid: 21994953
[3]	陈子江, 田秦杰, 乔杰, 等. 早发性卵巢功能不全的临床诊疗中国专家共识[J]. 中华妇产科杂志, 2017, 52(9):577-581. doi: 10.3760/cma.j.issn.0529-567x.2017.09.001. doi: 10.3760/cma.j.issn.0529-567x.2017.09.001
[4]	Popat VB, Vanderhoof VH, Calis KA, et al. Normalization of serum luteinizing hormone levels in women with 46,XX spontaneous primary ovarian insufficiency[J]. Fertil Steril, 2008, 89(2):429-433. doi: 10.1016/j.fertnstert.2007.02.032. doi: 10.1016/j.fertnstert.2007.02.032 URL
[5]	Tartagni M, Cicinelli E, De Pergola G, et al. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial[J]. Fertil Steril, 2007, 87(4):858-861. doi: 10.1016/j.fertnstert.2006.08.086. doi: 10.1016/j.fertnstert.2006.08.086 pmid: 17261285
[6]	Dragojevic Dikic S, Vasiljevic M, Jovanovic A, et al. Premature ovarian insufficiency-novel hormonal approaches in optimizing fertility[J]. Gynecol Endocrinol, 2020, 36(2):162-165. doi: 10.1080/09513590.2019.1640203. doi: 10.1080/09513590.2019.1640203
[7]	van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy[J]. Hum Reprod Update, 1999, 5(5):483-492. doi: 10.1093/humupd/5.5.483. doi: 10.1093/humupd/5.5.483 pmid: 10582785
[8]	Vendola KA, Zhou J, Adesanya OO, et al. Androgens stimulate early stages of follicular growth in the primate ovary[J]. J Clin Invest, 1998, 101(12):2622-2629. doi: 10.1172/JCI2081. doi: 10.1172/JCI2081 pmid: 9637695
[9]	高瑞璠, 土增荣, 王丽媛, 等. 脱氢表雄酮预处理对卵巢低反应患者体外受精/胞浆内单精子注射-胚胎移植临床结局的影响[J]. 国际生殖健康/计划生育杂志, 2019, 38(5):370-373. doi: 10.3969/j.issn.1674-1889.2019.05.004. doi: 10.3969/j.issn.1674-1889.2019.05.004
[10]	Yeung TW, Li RH, Lee VC, et al. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency[J]. J Clin Endocrinol Metab, 2013, 98(1):380-388. doi: 10.1210/jc.2012-3071. doi: 10.1210/jc.2012-3071 URL
[11]	Wong Q, Yeung T, Yung S, et al. The effect of 12-month dehydroepiandrosterone supplementation on the menstrual pattern, ovarian reserve markers, and safety profile in women with premature ovarian insufficiency[J]. J Assist Reprod Genet, 2018, 35(5):857-862. doi: 10.1007/s10815-018-1152-2. doi: 10.1007/s10815-018-1152-2 URL
[12]	Kim JJ, Accili D. Signalling through IGF-I and insulin receptors: where is the specificity?[J]. Growth Horm IGF Res, 2002, 12(2):84-90. doi: 10.1054/ghir.2002.0265. doi: 10.1054/ghir.2002.0265 URL
[13]	Li J, Chen Q, Wang J, et al. Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial[J]. BMC Pregnancy Childbirth, 2020, 20(1):310. doi: 10.1186/s12884-020-03004-9. doi: 10.1186/s12884-020-03004-9 URL
[14]	Cozzolino M, Cecchino GN, Troiano G, et al. Growth hormone cotreatment for poor responders undergoing in vitro fertilization cycles: a systematic review and meta-analysis[J]. Fertil Steril, 2020, 114(1):97-109. doi: 10.1016/j.fertnstert.2020.03.007. doi: S0015-0282(20)30252-1 pmid: 32553470
[15]	Gong Y, Zhang K, Xiong D, et al. Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial[J]. Reprod Biol Endocrinol, 2020, 18(1):91. doi: 10.1186/s12958-020-00648-2. doi: 10.1186/s12958-020-00648-2 URL
[16]	Busacca M, Fusi FM, Brigante C, et al. Success in inducing ovulation in a case of premature ovarian failure using growth hormone-releasing hormone[J]. Gynecol Endocrinol, 1996, 10(4):277-279. doi: 10.3109/09513599609012320. doi: 10.3109/09513599609012320 pmid: 8908529
[17]	Goud PT, Goud AP, Joshi N, et al. Dynamics of nitric oxide, altered follicular microenvironment, and oocyte quality in women with endometriosis[J]. Fertil Steril, 2014, 102(1):151-159.e5. doi: 10.1016/j.fertnstert.2014.03.053. doi: 10.1016/j.fertnstert.2014.03.053 URL
[18]	Wang S, Zheng Y, Li J, et al. Single-Cell Transcriptomic Atlas of Primate Ovarian Aging[J]. Cell, 2020, 180(3):585-600.e19. doi: 10.1016/j.cell.2020.01.009. doi: S0092-8674(20)30056-8 pmid: 32004457
[19]	He Q, Gu L, Lin Q, et al. The Immp21 Mutation Causes Ovarian Aging Through ROS-Wnt/β-Catenin-Estrogen Pathway: Preventive Effect of Melatonin[J]. Endocrinology, 2020, 161(9):bqaa119. doi: 10.1210/endocr/bqaa119. doi: 10.1210/endocr/bqaa119 URL
[20]	Zhang Y, Zhang C, Shu J, et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis[J]. Hum Reprod Update, 2020, 26(2):247-263. doi: 10.1093/humupd/dmz046. doi: 10.1093/humupd/dmz046 pmid: 32045470
[21]	Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment[J]. Proc Natl Acad Sci U S A, 2013, 110(43):17474-17479. doi: 10.1073/pnas.1312830110. doi: 10.1073/pnas.1312830110 URL
[22]	Zhang X, Han T, Yan L, et al. Resumption of Ovarian Function After Ovarian Biopsy/Scratch in Patients With Premature Ovarian Insufficiency[J]. Reprod Sci, 2019, 26(2):207-213. doi: 10.1177/1933719118818906. doi: 10.1177/1933719118818906 URL
[23]	Tanaka Y, Hsueh AJ, Kawamura K. Surgical approaches of drug-free in vitro activation and laparoscopic ovarian incision to treat patients with ovarian infertility[J]. Fertil Steril, 2020, 114(6):1355-1357. doi: 10.1016/j.fertnstert.2020.07.029. doi: 10.1016/j.fertnstert.2020.07.029 pmid: 32907748
[24]	Suzuki N, Yoshioka N, Takae S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency[J]. Hum Reprod, 2015, 30(3):608-615. doi: 10.1093/humrep/deu353. doi: 10.1093/humrep/deu353 URL
[25]	Zhai J, Yao G, Dong F, et al. In Vitro Activation of Follicles and Fresh Tissue Auto-transplantation in Primary Ovarian Insufficiency Patients[J]. J Clin Endocrinol Metab, 2016, 101(11):4405-4412. doi: 10.1210/jc.2016-1589. doi: 10.1210/jc.2016-1589 pmid: 27571179
[26]	Hsueh A, Kawamura K. Hippo signaling disruption and ovarian follicle activation in infertile patients[J]. Fertil Steril, 2020, 114(3):458-464. doi: 10.1016/j.fertnstert.2020.07.031. doi: 10.1016/j.fertnstert.2020.07.031 URL
[27]	Bos-Mikich A, de Oliveira R, Frantz N. Platelet-rich plasma therapy and reproductive medicine[J]. J Assist Reprod Genet, 2018, 35(5):753-756. doi: 10.1007/s10815-018-1159-8. doi: 10.1007/s10815-018-1159-8 URL
[28]	Pantos K, Nitsos N, Kokkali G, et al. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment[C]. Helsinki, Finland:ESHRE, 2016.
[29]	Ahmadian S, Sheshpari S, Pazhang M, et al. Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation[J]. Reprod Biol Endocrinol, 2020, 18(1):78. doi: 10.1186/s12958-020-00638-4. doi: 10.1186/s12958-020-00638-4 URL
[30]	Cakiroglu Y, Saltik A, Yuceturk A, et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency[J]. Aging (Albany NY), 2020, 12(11):10211-10222. doi: 10.18632/aging.103403. doi: 10.18632/aging.103403
[31]	Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience[J]. J Intern Med, 2007, 262(5):509-525. doi: 10.1111/j.1365-2796.2007.01844.x. doi: 10.1111/j.1365-2796.2007.01844.x pmid: 17949362
[32]	Trohatou O, Roubelakis MG. Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Past, Present, and Future[J]. Cell Reprogram, 2017, 19(4):217-224. doi: 10.1089/cell.2016.0062. doi: 10.1089/cell.2016.0062 pmid: 28520465
[33]	Su J, Ding L, Cheng J, et al. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency[J]. Hum Reprod, 2016, 31(5):1075-1086. doi: 10.1093/humrep/dew041. doi: 10.1093/humrep/dew041 URL
[34]	Mohamed SA, Shalaby SM, Abdelaziz M, et al. Human Mesenchymal Stem Cells Partially Reverse Infertility in Chemotherapy-Induced Ovarian Failure[J]. Reprod Sci, 2018, 25(1):51-63. doi: 10.1177/1933719117699705. doi: 10.1177/1933719117699705 pmid: 28460567
[35]	Ding L, Yan G, Wang B, et al. Transplantation of UC-MSCs on collagen scaffold activates follicles in dormant ovaries of POF patients with long history of infertility[J]. Sci China Life Sci, 2018, 61(12):1554-1565. doi: 10.1007/s11427-017-9272-2. doi: 10.1007/s11427-017-9272-2 URL